Department of Data Science, Princess Sumaya University for Technology, Amman, Jordan.
Department of Data Science, Princess Sumaya University for Technology, Amman, Jordan
BMJ Open. 2024 Feb 22;14(2):e078100. doi: 10.1136/bmjopen-2023-078100.
The consequences of type 2 diabetes mellitus (T2DM) heavily strain individuals and healthcare systems worldwide. Interventions via telemedicine have become a potential tactic to tackle the difficulties in effectively managing T2DM. However, more research is needed to determine how telemedicine interventions affect T2DM management. This study sets out to systematically analyse and report the effects of telemedicine treatments on T2DM management to gain essential insights into the potential of telemedicine as a cutting-edge strategy to improve the outcomes and care delivery for people with T2DM.
To uncover relevant research, we will perform a comprehensive literature search across six databases (PubMed, IEEE, EMBASE, Web of Science, Google Scholar and Cochrane Library). Each piece of data will be extracted separately, and any discrepancies will be worked out through discussion or by a third reviewer. The studies included are randomised controlled trial. We chose by predefined inclusion standards. After the telemedicine intervention, glycated haemoglobin will be the primary outcome. The Cochrane risk-of-bias approach will be used to evaluate the quality of the included studies. RevMan V.5.3.5 software and RStiduo V.4.3.1 software can be used to analyse the data, including publication bias.
Since this research will employ publicly accessible documents, ethical approval is unnecessary. The review is registered prospectively on the PROSPERO database. The study's findings will be published in a peer-reviewed journal.
CRD42023421719.
2 型糖尿病(T2DM)的后果给个人和全球医疗保健系统带来了沉重负担。远程医疗干预已成为有效管理 T2DM 困难的潜在策略。然而,需要更多的研究来确定远程医疗干预如何影响 T2DM 的管理。本研究旨在系统分析和报告远程医疗治疗对 T2DM 管理的影响,以深入了解远程医疗作为一种前沿策略的潜力,以改善 T2DM 患者的结局和护理提供。
为了发现相关研究,我们将在六个数据库(PubMed、IEEE、EMBASE、Web of Science、Google Scholar 和 Cochrane Library)中进行全面的文献搜索。将分别提取每一条数据,如果有任何差异,将通过讨论或由第三位审稿人解决。研究包括随机对照试验。我们根据预先设定的纳入标准进行选择。在远程医疗干预后,糖化血红蛋白将是主要结局。将使用 Cochrane 偏倚风险评估方法评估纳入研究的质量。RevMan V.5.3.5 软件和 RStiduo V.4.3.1 软件可用于分析数据,包括发表偏倚。
由于本研究将使用公开获取的文件,因此不需要伦理批准。该综述在 PROSPERO 数据库中进行了前瞻性注册。研究结果将发表在同行评议的期刊上。
PROSPERO 注册号:CRD42023421719。